Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Ro teams up with Eli Lilly to offer single-dose vials of weight loss drug Zepbound By Heather Landi Dec 12, 2024 8:00am Ro Eli Lilly Zepbound GLP-1 ...

The resulting dispute between Lilly and FDA – i.e. whether retatrutide is a biological product or drug – is important not only for Lilly, but for the future of the GLP-1 industry.

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound ...

“Today, Lilly filed two lawsuits against entities threatening patient safety by falsely promoting supposedly “personalized” compounded tirzepatide and misleading consumers about the safety, clinical ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Eli Lilly 's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial. The ...

Lilly announced on Thursday, Dec. 5 a $3 billion expansion of its Kenosha County manufacturing facility. Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this ...

Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed stocks on Cramer’s morning show. He is a fan of the firm not only due to its lead in the weight loss market but also due ...

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term ...